Drugdiscovery >> Drugs >> News
5423
Views
Breakthrough Therapy designation for leukemia drug Arzerra - drugdiscovery.com
Breakthrough Therapy designation for leukemia drug Arzerra - drugdiscovery.com


The FDA has granted Breakthrough Therapy designation for the drug Arzerra (ofatumumab), co-development by Genamb and GSK, used in combination with chlorambucil for the treatment of patients with chronic lymphocytic leukemia (CLL).
Read More >>


Tags: Arzerra, ofatumumab, chronic lymphocytic leukemia, CLL, breakthrough therapy designation - September 17, 2013
Related Articles
3263
Views
Breakthrough Therapy designation for AML drug volasertib Breakthrough Therapy designation for AML drug volasertib
The FDA has granted Breakthrough Therapy designation to Boehringer Ingelheim’s investigational compound - volasertib, for the treatment of patients with acute myeloid leukemia. Read More >>

Tags: volasertib, acute myeloid leukemia, Boehringer Ingelheim, breakthrough therapy,experimental drug

15736
Views
Breakthrough therapy designation for Roche’s lung cancer drug alectinib Breakthrough therapy designation for Roche’s lung cancer drug alectinib
The FDA has granted breakthrough therapy designation for Roche’s promising investigational 2nd generation ALK inhibitor, used for the treatment of patients with metastatic non-small cell lung cance Read More >>

Tags: alectinib, lung cancer, breakthrough therapy designation, Roche, investigational drug, ALK inhibitor, metastatic non-small cell lung cancer, NSCLC, FDA

5910
Views
Breakthrough Therapy Designation for Firdapse Breakthrough Therapy Designation for Firdapse
FDA has granted a Breakthrough Therapy Designation to Catalyst Pharmaceutical Partners for the drug Firdapse (amifampridine phosphate), for the symptomatic treatment of patients with Lambert-Eaton Mya Read More >>

Tags: Firdapse, Lambert-Eaton Myasthenic Syndrome, LEMS, orphan drug, breakthrough therapy

8661
Views
Novartis muscle drug gets breakthrough therapy designation Novartis muscle drug gets breakthrough therapy designation
The FDA granted a breakthrough therapy status to Novartis’ newly developed compound- bimagrumab (BYM338), used to treat a life-threatening muscle disease called sporadic inclusion body myositis tha Read More >>

Tags: Novartis, cancer cachexia,sarcopenia, COPD, bimagrumab, BYM338, sporadic inclusion body myositis, muscles, waste away

6006
Views
Orphan Drug Designation for ReN003 retinal stem cell therapy Orphan Drug Designation for ReN003 retinal stem cell therapy
ReNeuron Group’s ReN003 retinal stem cell therapy, candidate for retinitis pigmentosa, has been granted Orphan Drug Designation in both Europe and the U.S. Read More >>

Tags: Orphan Drug Designation, ReN003, retinal stem cell therapy, retinitis pigmentosa, orphan drug, stem cell therapy

7760
Views
Orphan drug designation for Delcath’s liver cancer drug Orphan drug designation for Delcath’s liver cancer drug
The FDA has granted "orphan drug" status to Delcath Systems’ melphalan hidrochloride chemotherapy for the treatment of primary liver cancer (hepatocellular carcinoma). Read More >>

Tags: melphalan, liver cancer, US, orphan drug, designation, hepatocellular carcinoma, Delcath

5406
Views
Orphan drug designation for Bayer’s hypertension drug riociguat Orphan drug designation for Bayer’s hypertension drug riociguat
The FDA has granted two separate orphan drug designations for riociguat, Bayer’s investigational hypertension drug, for the treatment of pulmonary arterial hypertension and chronic thromboembolic pu Read More >>

Tags: riociguat, hypertension, drug, orphan drug designation, orphan, Bayer, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

4489
Views
Rituxan and Arzerra get a boxed warning of HBV risk Rituxan and Arzerra get a boxed warning of HBV risk
The anti-CD20-directed monoclonal antibodies used to treat chronic lymphocytic leukemia, rituximab (Rituxan) and ofatumumab (Arzerra), will from now carry a boxed warning of the risk for immunosuppres Read More >>

Tags: Rituxan, Arzerra, warning, HBV, risk

3576
Views
Patient enrollment in all clinical studies of leukemia drug Iclusig paused Patient enrollment in all clinical studies of leukemia drug Iclusig paused
The FDA has put on hold patient enrollment in all clinical studies of Ariad Pharmaceuticals’ leukemia drug Iclusig (ponatinib) due to arterial and venous adverse events in treated patients. Changes Read More >>

Tags: Patient enrollment, clinical studies, leukemia, drug, Iclusig, ponatinib, Ariad

5352
Views
Priority Review designation for Nexavar Priority Review designation for Nexavar
FDA has granted Priority Review designation for the Bayer HealthCare’s and Onyx Pharmaceuticals’ oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of local Read More >>

Tags: Nexavar, sorafenib, thyroid cancer, advanced, Bayer HealthCare, Onyx Pharmaceuticals, priority review designation, FDA

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013